Description
Adc is under investigation for the treatment of colorectal cancer and its clinical utility in this setting has not been established. It may be used as part of a combination therapy but more research is needed to define its role in CRC management.
Mechanism of Action
Adc is an investigational agent and its mechanism of action has not been fully elucidated for colorectal cancer (CRC). It targets specific proteins or receptors overexpressed in CRC cells, potentially inhibiting tumor growth.
Side Effects
Hematological toxicity; gastrointestinal symptoms; fatigue; neurotoxicity
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
NCT07145255
med_phase_prefix1
Recruiting
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
United States
NCT05286814
med_phase_prefix2
Recruiting
PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
United States
NCT04708470
med_phase_prefix1
Active, not recruiting
A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers
United States
NCT03621982
med_phase_prefix1
Archived
Study of ADCT-301 in Patients With Selected Advanced Solid Tumors
United States, Belgium, United Kingdom